DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 1 Venki - 1 Ramakrishnan - 1 He's - 1 Michael Pollan's - 1
Top related locs:
Cambridge
Top related orgs:
Service - 1 Royal Society - 1 Business - 1 Allied Market Research - 1 FDA - 1 British - 1 of Sports Medicine - 1 American College of Cardiology's - 1

Search resuls for: "American College of Cardiology's"


2 mentions found


☆ A Nobel Prize-winning scientist who wrote a book on aging cycles 6 miles a day at age 72. Here are 3 things he does to stay healthy.
  + stars: | 2024-11-08 | by ( Kim Schewitz | ) www.businessinsider.com   time to read: +6 min
download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementVenki Ramakrishnan, a Nobel laureate and former president of the world's oldest scientific academy, the Royal Society, has been watching as aging science and the hype around it has exploded. There have been some real scientific breakthroughs, deepening our understanding of the fundamental causes of aging, Ramakrishnan told Business Insider. AdvertisementCycling everydayExercise has all kinds of benefits for healthy aging, Ramakrishnan said. Research suggests that getting enough good quality sleep could add a few years to your life.
Persons: —, Venki, Ramakrishnan, He's, Michael Pollan's Organizations: Service, Royal Society, Business, Allied Market Research, FDA, British, of Sports Medicine, American College of Cardiology's Locations: Cambridge
☆ Merck's drug boosts exercise capacity in pulmonary hypertension patients
  + stars: | 2023-03-06 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +2 min
Sotatercept, combined with a background therapy, helped patients with pulmonary arterial hypertension to walk about 40.8 meters more in six minutes. J.P. Morgan analyst Chris Schott said the data exceeded the brokerage's expectations and "should confirm the drug as go-to add-on therapy" for pulmonary arterial hypertension. Schott forecast peak sales of $3 billion to $4 billion for the drug. In October, Merck said sotatercept had met the main goal of a late-stage study, but did not release the full data. Reporting by Khushi Mandowara and Pratik Jain in Bengaluru; Editing by Arun Koyyur and Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 2